Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery
Posted inDiabetes & Endocrinology Gastroenterology news

Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery

Researchers developed and validated the FMO score, a noninvasive, cost-effective tool to identify at-risk metabolic dysfunction-associated steatohepatitis (MASH) in obese patients, showing strong predictive performance across multiple international cohorts.